COVID-19 (omicron JN.1) vaccine is under clinical development by Moderna and currently in Pre-Registration for Coronavirus Disease 2019 (COVID-19).

All new Pfizer and Moderna vaccines target the Omicron variant KP.2 strain of SARS-CoV-2, the virus that causes COVID. Spikevax, the COVID-19 vaccine manufactured by Moderna and FDA-approved for ...

With COVID vaccine sales in the doldrums and a respiratory syncytial virus (RSV) vaccine market in “contraction”, Moderna CEO ...

The new vaccine is an updated version of Moderna's widely-use Spikevax vaccine, which includes sequences from the original Wuhan strain of SARS-CoV-2, as well as from the Omicron BA.1 subvariant.

The challenge of maintaining the earlier growth achieved by US mRNA medicines specialist Moderna through its COVID vaccine ...

Moderna, a leader in mRNA medicine, developed one of the earliest COVID-19 vaccines, with Spikevax being its first commercial product. The company's mRNA platform enables the development of ...

Moderna's sales were almost entirely from Spikevax, its coronavirus vaccine. It also had a 40% share of the U.S. commercial coronavirus vaccine market. Moderna will likely remain a leader in this ...

Moderna faces index removal, stock plunge, vaccine challenges, and lawsuits, while focusing on R&D in oncology and rare diseases for future growth.

Most common adverse events reported after receiving the Moderna (Spikevax) vaccine against COVID-19 in Spain as of December 31, 2022 ...